Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00376727 · ClinicalTrials.gov registry record · Phase 1
Cetuximab in Treating Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by University of California, Davis.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT00376727 is a Phase 1 study that has completed, run by University of California, Davis. The registered enrollment target is 27 participants.
The verdict
NCT00376727, a Phase 1 study, has completed, sponsored by University of California, Davis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. PURPOSE: This phase I trial is studying the side effects and best dose of cetuximab in treating patients with advanced solid tumors.
Interventions
- OTHER laboratory biomarker analysis
- BIOLOGICAL cetuximab
- OTHER immunologic technique
- GENETIC molecular diagnostic method
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2004-12 |
| Est. Completion | 2007-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00376727
The ClinicalTrials.gov registry entry for NCT00376727 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT00376727 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00376727 about?
NCT00376727 is a clinical study titled "Cetuximab in Treating Patients With Advanced Solid Tumors". RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. PURPOSE: This phase I trial is studying the side effects and...
What is the current status of trial NCT00376727?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2004-12. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00376727?
The interventions under investigation include: laboratory biomarker analysis (OTHER), cetuximab (BIOLOGICAL), immunologic technique (OTHER), molecular diagnostic method (GENETIC).
Who is sponsoring clinical trial NCT00376727?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.